ArticleRheumatology and therapy2021

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China.

SiNi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.